Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker ADAPY
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Sep 26, 2025 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Sep 12, 2025 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Sep 8, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 29, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 14, 2025 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Aug 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 7, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jul 31, 2025 | ADAPY Adaptimmune Therapeutics PLC | 2.01 Completion of Acquisition or Disposition of Assets | 8-K | 8-K ↗ |
| Jul 31, 2025 | ADAPY Adaptimmune Therapeutics PLC | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 28, 2025 | ADAPY Adaptimmune Therapeutics PLC | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 28, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jul 28, 2025 | ADAPY Adaptimmune Therapeutics PLC | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Jul 28, 2025 | ADAPY Adaptimmune Therapeutics PLC | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 17, 2025 | ADAPY Adaptimmune Therapeutics PLC | 8.01 Other Events | 8-K | 8-K ↗ |
| May 29, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 1, 2025 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Apr 14, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 24, 2025 | ADAPY Adaptimmune Therapeutics PLC | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 19, 2024 | ADAPY Adaptimmune Therapeutics PLC | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 19, 2024 | ADAPY Adaptimmune Therapeutics PLC | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 13, 2024 | ADAPY Adaptimmune Therapeutics PLC | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Nov 13, 2024 | ADAPY Adaptimmune Therapeutics PLC | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 13, 2024 | ADAPY Adaptimmune Therapeutics PLC | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 1, 2024 | ADAPY Adaptimmune Therapeutics PLC | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:39 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances